Prenatal diagnosis

Free DNA Fetal RhD kit

Fetal genotyping kit rhd from maternal blood sample

Based on the detection of free circulating fetal DNA ("cff DNA") present from the 7th SA in maternal blood, our kit allows early diagnosis (11th SA) of the fetal RHD genotype in the context of an Rh- woman pregnancy. Performed on a simple maternal blood sample, this test avoids unnecessary and potentially risky injections of anti-D immunoglobulins and reduces the follow-up of RhD- female pregnancies.
It is prescribed by gynecologists and midwives and performed by accredited laboratories.

Quantification of feto-maternal hemorrhage

K-Matic & Easy-K

Staining automaton and support for your Kleihauer tests

By highlighting the presence of fetal red cells in the maternal blood and quantifying their proportion, the Kleihauer test makes it possible to adapt the quantity of anti-D immunoglobulin to be injected to the future mother in the context of the prevention of RhD fetomaternal alloimmunization in RhD negative women.
By partially or fully standardizing the Kleihauer test, the range dedicated to feto-maternal quantification allows laboratories to secure the achievement of staining.

Research and tailor-made

Cellular culture

Research use only

Besides our range of CE-IVD products, we offer a range
of human sera and collagen to organizations carrying out research.

Internal Quality Controls

Reliable IQC

control samples for laboratory techniques

Medical laboratories are required to verify the quality and reliability of the results of their analyzes, using internal quality control materials comparable to any patient sample. IBJB offers CQIs that meet the highest quality requirements. The CQI-IH are also independent, their results are known and guaranteed for any technique without restriction (filtration columns, plate, tube, microplate).
Our values
Collaboration
Engagement
Respect
Trust
Arrangement

  • 2019-2020
    Every day, our teams continue to innovate, search, test, improve, to advance prenatal medicine accessible to all.

  • 2017
    In July, the prenatal determination of fetal RHD genotype from maternal blood is included in the nomenclature of medical biology acts. IBJB allows this test to be carried out thanks to its "Free DNA Fetal Kit® RhD" box certified CE IVD by the LNE / GMED according to Annex II List A, and which thus complies with the requirements of Directive 98/79 / EC and the Public Health Code. The Institute responds to the needs of the largest French medical biology laboratories with accreditation for prenatal biological diagnosis, as well as specialized foreign laboratories.

  • 2015
    In June, Institut de Biotechnologies Jacques Boy distributes the Free DNA Fetal Kit® RhD and provides the dedicated technical support.

  • 2014
    K-Matic®, an innovative device developed by Institut de Biotechnologies Jacques Boy, is released onto the market. It automates the Kleihauer test, releases valuable time, ensuring cleanliness, reliability and traceability.

  • 2007
    IBJB markets its "Free DNA Fetal Kit® RhD" IVD medical device, which meets the requirements of the EC / 98/79 Directive, enabling robust, specific and sensitive tests to be performed for prenatal determination of the fetal RHD genotype from maternal blood.

  • 2006
    Public / private collaboration on the genotyping project is continuing. It is the subject of an application for innovation funds from Oséo, which is up to day fully reimbursed.

  • 2004
    The Jacques Boy S.A. Institute leaves the Public Hospital site and moves into new laboratories at the Henri Farman Technological Center in Reims. It becomes "Institut de Biotechnologies Jacques Boy (IBJB)".

  • 2002
    IBJB decides to finance a study carried out by the National Reference Center for Perinatal Hemobiology (CNRHP-Paris St Antoine) and the INSERM U76-INTS-PARIS unit, on fetal RHD genotyping, via an analysis of the Fetal DNA circulating in the maternal blood. It aims to demonstrate the feasibility and reliability of large scale screening using this technique. It has been the subject of a scientific article published in Molecular Diagnosis (Volume 8, Issue 1, Pages 23-31): "Large-Scale Pre-Diagnosis Study of Fetal RHD Genotyping by PCR on DNA Plasma from RhD-Negative Pregnant Women ", written by Christelle Rouillac-Le Sciellour, Phillippe Puillandre, Rolande Gillot, Céline Baulard, Sylvain Métral, Caroline Le Van Kim, Jean-Pierre Cartron, Yves Colin and Yves Brossard.

  • 2002
    Institut de Biotechnologies Jacques Boy (IBJB) is modernizing strongly, quality is present at all levels. The establishment is certified ISO 9001 and NF ISO 13485. Thanks to its responsiveness it becomes the first company in France to manufacture boxes for internal quality control in immunohematology to be distributed by DiaMed France. Market share quickly rises to 60%.

  • 1998
    A collaboration is taking shape with DiaMed, world leader in Immuno-Hematology (they're the designer of gel filtering which became a reference), which concludes with cross agreements resulting in an effective synergy.

Our history
Key dates
Our strengths
The choice of independence at a human size
Institut de Biotechnologies Jacques Boy is 100% independent & French

The history of the Jacques Boy Institute is above all a story of men and will! An always fierce desire to preserve our independence especially in comparison with other large groups. In 1985, our laboratory was born at the initiative of the Regional Center for Blood Transfusion of Reims, and it took the name of the creator of this RCBT: Professor Jacques Boy, biologist and professor of hematology. Since then we have been imagining, developing and manufacturing laboratory reagents for blood grouping. And more recently, we have become in a few years, a recognized actor in French medical biology for prenatal diagnostics.
Our fights
Advancing Research for Women
In 2017, after several years of struggle, we managed to have, with the support of professional unions and expert groups, Fetal RHD genotyping from maternal blood registered to the French nomenclature of reimbursed acts, easing the follow-up of the pregnancy of RhD- women and, as often as possible, avoiding them heavy, expensive and risky treatments.
A responsible company
releasing management
As a citizen corporation, the IBJB affirms its social and environmental responsibility, in its mission, in its management methods, and in its historical and strong involvement with its territory.
We use cookies to improve your experience and deliver personalized content.
By using our site, you agree to our Privacy Policy.
 
Read more